February 15, 2017 (Ft. Lauderdale, Florida)
Precision Medical Devices (PMD) has just obtained a new patent allowance for components of its flow control device (FCD) product, which has been designed to treat, among other medical conditions, severe urinary incontinence (UI).
The new patent represents the ninth patent obtained in the US for its FCD product and the twenty-seventh patent, worldwide, for the Company.
The new patent is a divisional to another of our US-issued patents.
The patents obtained by the Company in the US are of key importance as the US patents represent the primary patent applications for the Company’s technology, which become the basis for all of our other foreign patent applications.
Notwithstanding the years the Company has been developing the product and technology, the Company has been able to acquire more than 45% of its intellectual property protections just since 2010, including essential updates of the Company’s technology, as well as, initial patent coverage in most of the other worldwide markets (outside the US) we have targeted.
The new patent describes some of the Company’s proprietary intellectual property features that relates to our device’s unique technology including a new an innovated means of transmitting and receiving telemetry signals from and to our implanted device without interference from our titanium control pack cover yet continues to maintain the hermetic seal of the control pack and adds a number of claims of uniqueness to our intellectual property protections now exceeding 180 such claims.
The FCD represents unique, fully implantable remote-controlled and remote telemetrically-adjustable (via Bluetooth) technology that was designed to treat the severest forms of urinary incontinence (UI); cases which were previously undertreated or untreatable by any current device product or procedure.
The Company further expects that such technology will be usable to treat a number of other medical conditions, including, but not limited to; fecal incontinence, morbid obesity, GERDs and ED.